|
Trial
|
ML18147 Ref. [11]
|
RAISE Ref. [4]
|
VELOUR Ref. [3]
|
|---|
|
Number of cases
|
820
|
1072
|
1226
|
|
Prior oxaliplatin
|
41.8%
|
100%
|
100%
|
|
Prior bevacizumab
|
100%
|
100%
|
30.5%
|
|
Backbone chemotherapy
|
Irinotecan (35%)
|
FOLFIRI
|
FOLFIRI
|
|
Design
|
Open label
|
Double blind
|
Double blind
|
|
Combination
|
With BEV
|
Without BEV
|
With RAM
|
Without RAM
|
With AFL
|
Without AFL
|
|
ORR
|
5%
|
3%
|
13.4%
|
12.5%
|
19.8%
|
11.1%
|
|
PFS (months)
|
5.7
|
4.1
|
5.7
|
4.5
|
6.90
|
4.67
|
| |
HR 0.68
|
p < .0001
|
HR0.793
|
p < .0005
|
HR0.758
|
p < .0001
|
|
OS (months)
|
11.2
|
9.8
|
13.3
|
11.7
|
13.50
|
12.06
|
| |
HR 0.81
|
p = .0062
|
HR 0.844
|
p = .0219
|
HR 0.817
|
p = .0032
|
- ORR overall response rate, PFS progression-free survival, OS overall survival, BEV bevacizumab, RAM ramucirumab, AFL aflibercept
